Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Heme oxygenase-1 (HO-1)
100%
Drug Development
80%
TAR DNA-binding Protein 43 (TDP-43)
80%
Reporter Expression
80%
Early Biomarker
80%
Degenerative Disease
80%
Glioblastoma
80%
High-intensity Focused Ultrasound
80%
Low Intensity
80%
Nuclear Factor Erythroid 2-related Factor 2 (Nrf2)
80%
Oxidative Stress
80%
Methyl
80%
Antimicrobial Activity
80%
Copper-catalyzed Azide-alkyne Cycloaddition (CuAAC)
80%
ESKAPE Pathogens
80%
Indole
80%
Pyrazolone
80%
Chemical Mixtures
80%
Transgenerational Effects
80%
Aroclor 1254
80%
1,2,3-triazole
80%
Toxicity Mechanism
80%
Multidrug-resistant
80%
Synthesized Compounds
80%
Transcriptional Profiling
80%
In Vitro Stress
80%
Clinical Trials
66%
Reporter Mice
60%
In Vivo Reporter
60%
Ablation
53%
Glioblastoma Therapy
53%
Drug Delivery
53%
Focused Ultrasound
53%
Recent Advances
40%
Inflammation
40%
Histological Analysis
40%
Disease Progression
40%
Neurodegenerative Diseases
40%
Clinical Signs
40%
Cellular Stress
40%
DNA Damage
40%
P53 Pathway
40%
Cellular Damage
40%
Specific Mechanisms
40%
2-phenyl-2
40%
Nrf2 Pathway
40%
Therapeutic Interventions
40%
Cytotoxicity
40%
Bacterial Infection
40%
Methylene
40%
Pharmacology, Toxicology and Pharmaceutical Science
Antiinfective Agent
80%
Indole
80%
Infectious Agent
80%
Triazole
80%
Pyrazolone
80%
Cytotoxicity
80%
Aroclor 1254
80%
Clinical Study
80%
Preclinical Study
80%
Glioblastoma
80%
Bacterial Infection
40%
Nystatin
40%
Tolerability
40%
Mycosis
40%
Antifungal Activity
40%
Carbene
40%
Gram Negative Bacterium
40%
Azide
40%
Candida Albicans
40%
Alkyne
40%
Fluconazole
40%
Antimicrobial Agent
40%
Chloramphenicol
40%
Aspergillus Niger
40%
Pyrazole
40%
Ampicillin
40%
Acinetobacter Baumannii
40%
Click Chemistry
40%
Blood-Brain Barrier
32%
Inflammation
20%
Polychlorinated Biphenyl
20%
Xenobiotic Metabolism
20%
Aromatic Hydrocarbon Receptor
20%
Transcriptome
20%
Transcription Factor Nrf2
20%
Maternal Exposure
20%
Carcinogenesis
20%
Clinical Trial
16%
Overall Survival
16%
Tumor Growth
16%
Temozolomide
16%
Randomized Controlled Trial
16%
Immunotherapy
16%
Progression Free Survival
16%
Chemotherapy Regimens
16%
Recurrence Risk
16%
Intracranial Tumor
16%
Cancer Inhibition
16%
Nanoparticle
16%
Adverse Event
16%
